Scarica l'app Stockscreener
2.13
0.95%
0.02
Dopo l'orario di chiusura:
2.13
Precedente Chiudi:
$2.11
Aprire:
$2.13
Volume 24 ore:
5.04M
Relative Volume:
0.54
Capitalizzazione di mercato:
$732.67M
Reddito:
$22,000
Utile/perdita netta:
$-190.89M
Rapporto P/E:
-2.4534
EPS:
-0.8682
Flusso di cassa netto:
$-149.63M
1 W Prestazione:
-9.36%
1M Prestazione:
-4.05%
6M Prestazione:
+76.03%
1 anno Prestazione:
+26.79%
Intervallo 1D:
$2.105
$2.175
Intervallo di 1 settimana:
$2.09
$2.39
Portata 52W:
$0.8621
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Nome
Allogene Therapeutics Inc
Settore
Industria
Telefono
(650) 457-2700
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.13 | 753.31M | 22,000 | -190.89M | -149.63M | -0.8682 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2026-04-10 | Ripresa | Jefferies | Buy |
| 2026-01-09 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Ripresa | Oppenheimer | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-05 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-08-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-28 | Reiterato | B. Riley Securities | Buy |
| 2021-10-20 | Iniziato | Cowen | Outperform |
| 2021-10-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-10-08 | Downgrade | Stifel | Buy → Hold |
| 2021-09-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Ripresa | Jefferies | Buy |
| 2021-05-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-01-26 | Aggiornamento | Stifel | Hold → Buy |
| 2020-12-10 | Ripresa | H.C. Wainwright | Buy |
| 2020-11-24 | Iniziato | BofA Securities | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-06-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-19 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Downgrade | SunTrust | Buy → Hold |
| 2020-04-13 | Iniziato | SunTrust | Buy |
| 2020-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-24 | Iniziato | Berenberg | Hold |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-05 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Neutral |
| 2019-05-23 | Iniziato | Stifel | Hold |
| 2019-03-29 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN
ALLO stock hits 2-year highs – analyst calls Allogene’s phase 2 trial data to treat lymphoma a ‘home run’ - MSN
Pfizer in deal with Allogene to develop cancer cell therapies - AOL.com
Allogene Therapeutics stock hits 52-week highhere's why - MSN
Allogene Therapeutics unveils ALLO-329 to target autoimmune disease with allogeneic CAR-T approach - Traders Union
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Allogene licensor Cellectis faces patent lawsuit in the U.S. - MSN
JP Morgan Upgrades Allogene Therapeutics (ALLO) - MSN
JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Allogene Therapeutics prices $175M stock offering at $2 per share - MSN
Allogene jumps on analysis of Phase 2 data for B-cell lymphoma asset cema-cel - MSN
Allogene Therapeutics Expands Cancer Trial into South Korea and Australia - HarianBasis.co
Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In - Yahoo Finance
10 Best Growth Stocks Under $10 to Invest In - Insider Monkey
Allogene Therapeutics aims to redefine CAR T therapy with scalable allogeneic approach - Traders Union
Allogene Therapeutics announces public offering of $175M of common stock - MSN
Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares - MarketBeat
[SCHEDULE 13G] Allogene Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Allogene (NASDAQ: ALLO) SVP sale covers RSU taxes, holds 124,517 shares - Stock Titan
Allogene Therapeutics VP joins FiercePharmaEngage to drive M and A strategies in allogeneic cell therapy - Traders Union
Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO) - The Globe and Mail
H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO) - Insider Monkey
Allogene expands lymphoma trial to South Korea, Australia By Investing.com - Investing.com India
Allogene Therapeutics Inc (ALLO) News, Articles, Events & Latest Updates - Stocktwits
Allogene Therapeutics, Inc.Common Stock (NQ: ALLO - FinancialContent
Allogene (NASDAQ: ALLO) RSU vests 9,586 shares; Form 144 filed 04/21/2026 - Stock Titan
Allogene Therapeutics drives international momentum with ALPHA3 trial and targets Q2 2026 screening - Traders Union
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6%Should You Sell? - MarketBeat
Allogene Therapeutics (ALLO) Expands Groundbreaking Study in Sou - GuruFocus
Allogene Therapeutics Cleared to Expand B-Cell Lymphoma Treatment Trial in South Korea, Australia - marketscreener.com
Allogene expands lymphoma trial to South Korea, Australia - Investing.com
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewswire
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript - MSN
Allogene (NASDAQ: ALLO) proxy urges approval to raise authorized shares to 800M - Stock Titan
Latham & Watkins Advises on Allogene Therapeutics’ US$200.4 Million Public Offering of Common Stock - Legal Desire Media and Insights
Allogene Therapeutics presents dual CAR-T cell data for high-risk myeloma after BCMA therapy - Traders Union
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - The Manila Times
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene raises $200.4 million in stock offering By Investing.com - Investing.com India
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - Sahm
ALLO Upgraded by JP Morgan -- Rating Changed to Neutral - GuruFocus
Allogene Therapeutics advances allogeneic CAR T interim results in early LBCL consolidation - Traders Union
ALLO Stock Rockets As ALPHA3 CAR‑T Data Reset Expectations - timothysykes.com
Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):